{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-036888","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.727293+00:00","generated_at":"2026-06-08T21:25:36.123739+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MoonLake Phase 2 ARGO trial meets primary endpoint; sonelokimab ACR50 46-47% vs placebo","bullets":["ACR50 achieved by 46% (60mg) and 47% (120mg) with induction at week 12 (p<0.01 vs placebo; ITT-NRI).","Key secondary endpoint PASI90 reached by 77% (60mg) and PASI100 by 58% (60mg) at week 12.","Discontinuation rate <4%; no new safety signals; oral candidiasis <2%, no IBD/MACE/SI/B.","Sonelokimab numerically outperformed adalimumab on primary and key secondary endpoints.","Company plans Phase 3 in PsA; end-of-Phase 2 regulatory meeting timing to be announced."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-036888","json":"https://secwatch.observer/filing/0001628280-23-036888.json","markdown":"https://secwatch.observer/filing/0001628280-23-036888.md","text":"https://secwatch.observer/filing/0001628280-23-036888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000162828023036888/0001628280-23-036888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000162828023036888/mltx-20231105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:25:36.123739+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}